The Opportunities and Challenges of Molecular Tagging Next-Generation Sequencing in Liquid Biopsy.
Journal
Molecular diagnosis & therapy
ISSN: 1179-2000
Titre abrégé: Mol Diagn Ther
Pays: New Zealand
ID NLM: 101264260
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
accepted:
20
06
2021
pubmed:
6
7
2021
medline:
14
1
2022
entrez:
5
7
2021
Statut:
ppublish
Résumé
Liquid biopsy (LB) is a promising tool that is rapidly evolving as a standard of care in early and advanced stages of cancer settings. Next-generation sequencing (NGS) methods have become essential in molecular diagnostics and clinical laboratories dealing with LB analytes, i.e., cell-free DNA and RNA. The sensitivity and high-throughput capacity of NGS enable us to overcome technical issues that are mainly attributable to low-abundance (below 1% mutated allelic frequency) tumour genetic material circulating within biological fluids. In this context, the introduction of unique molecular identifiers (UMIs), also known as molecular barcodes, applied to various NGS platforms greatly improved the characterization of rare genetic alterations, as they resulted in a drastic reduction in background noise while maintaining high levels of positive predictive value and sensitivity. Different UMI strategies have been developed, such as single (e.g., safe-sequencing system, Safe-SeqS) or double (duplex-sequencing system, Duplex-Seq) strand-based labelling, and, currently, considerable results corroborate their potential implementation in a routine laboratory. Recently, the US Food and Drug Administration approved the clinical use of two comprehensive UMI-based NGS assays (FoundationOne Liquid CDx and Guardant360 CDx) in cfDNA mutational assessment. However, to definitively translate LB into clinical practice, UMI-based NGS protocols should meet certain feasibility requirements in terms of cost-effectiveness, wet laboratory performance and easy access to web-source and bioinformatic tools for downstream molecular data.
Identifiants
pubmed: 34224097
doi: 10.1007/s40291-021-00542-6
pii: 10.1007/s40291-021-00542-6
doi:
Substances chimiques
Cell-Free Nucleic Acids
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
537-547Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Bardelli A, Pantel K. Liquid biopsies, What we do not know (yet). Cancer Cell. 2017;31(2):172–9.
doi: 10.1016/j.ccell.2017.01.002
Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic—implementation issues and future challenges. Nat Rev Clin Oncol. 2021. https://doi.org/10.1038/s41571-020-00457-x (Epub ahead of print. PMID: 33473219.).
doi: 10.1038/s41571-020-00457-x
pubmed: 33473219
Oxnard GR, Thress KS, Alden RS, Lawrance R, Paweletz CP, Cantarini M, et al. Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer. J Clin Oncol. 2016;34:3375–82.
doi: 10.1200/JCO.2016.66.7162
US Food & Drug Administration. Premarket approval P150044—Cobas EGFR MUTATION TEST V2.FDA. 2016. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P150044 .
André F, Ciruelos E, Juric D, Loibl S, Campone M, Mayer IA, et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019;380:1929–40.
doi: 10.1056/NEJMoa1813904
Santini D, Vincenzi B, Addeo R, Garufi C, Masi G, Scartozzi M, et al. Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? Ann Oncol. 2012;23(9):2313–8. https://doi.org/10.1093/annonc/mdr623 .
doi: 10.1093/annonc/mdr623
pubmed: 22396447
Liu X, George GC, Tsimberidou AM, Naing A, Wheler JJ, Kopetz S, et al. Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. BMC Cancer. 2015;15:713.
doi: 10.1186/s12885-015-1701-3
Parseghian CM, Loree JM, Morris VK, Liu X, Clifton KK, Napolitano S, et al. Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. Ann Oncol. 2019;30(2):243–9.
doi: 10.1093/annonc/mdy509
Luo H, Zhao Q, Wei W, Zheng L, Yi S, Li G, et al. Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer. Sci Transl Med. 2020;12(524):533. https://doi.org/10.1126/scitranslmed.aax7533 (Erratum in: Sci Transl Med. 2020;12(540): PMID: 31894106).
doi: 10.1126/scitranslmed.aax7533
Berger LA, Janning M, Velthaus JL, Ben-Batalla I, Schatz S, Falk M, et al. Identification of a high-level MET amplification in CTCs and cfTNA of an ALK-positive NSCLC patient developing evasive resistance to crizotinib. J Thorac Oncol. 2018;13(12):e243–6. https://doi.org/10.1016/j.jtho.2018.08.2025 (Epub 2018 Sep 8 PMID: 30205165).
doi: 10.1016/j.jtho.2018.08.2025
pubmed: 30205165
Raez L, Danenberg K, Hunis B, Castrellon A, Jaimes Y, Velez M, et al. P203b–039 Cell-Free (cf) DNA and cfRNA levels in plasma of lung cancer patients indicate disease status and predict progression. Topic Biomark J Thorac Oncol. 2017;12(1):959. https://doi.org/10.1016/j.jtho.2016.11.1320 .
doi: 10.1016/j.jtho.2016.11.1320
Ishiba T, Hoffmann AC, Usher J, Elshimali Y, Sturdevant T, Dang M, et al. Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types. Biochem Biophys Res Commun. 2018;500(3):621–5. https://doi.org/10.1016/j.bbrc.2018.04.120 (Epub 2018 Apr 30 PMID: 29679564).
doi: 10.1016/j.bbrc.2018.04.120
pubmed: 29679564
Escors D, Gato-Cañas M, Zuazo M, Arasanz H, García-Granda MJ, Vera R, et al. The intracellular signalosome of PD-L1 in cancer cells. Signal Transduct Target Ther. 2018;3:26. https://doi.org/10.1038/s41392-018-0022-9.PMID:30275987;PMCID:PMC6160488 .
doi: 10.1038/s41392-018-0022-9.PMID:30275987;PMCID:PMC6160488
pubmed: 30275987
pmcid: 6160488
Bidard FC, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol. 2014;15(4):406–14. https://doi.org/10.1016/S1470-2045(14)70069-5 (Epub 2014 Mar 11 PMID: 24636208).
doi: 10.1016/S1470-2045(14)70069-5
pubmed: 24636208
Lorente D, Olmos D, Mateo J, Bianchini D, Seed G, Fleisher M, et al. Decline in circulating tumor cell count and treatment outcome in advanced prostate cancer. Eur Urol. 2016;70(6):985–92. https://doi.org/10.1016/j.eururo.2016.05.023 (Epub 2016 Jun 9. PMID: 27289566; PMCID: PMC5568108).
doi: 10.1016/j.eururo.2016.05.023
pubmed: 27289566
pmcid: 5568108
Cristofanilli M, Pierga JY, Reuben J, Rademaker A, Davis AA, Peeters DJ, et al. The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. Crit Rev Oncol Hematol. 2019;134:39–45.
doi: 10.1016/j.critrevonc.2018.12.004
González-Silva L, Quevedo L, Varela I. Tumor functional heterogeneity unraveled by scRNA-seq technologies: (Trends in Cancer). Trends Cancer. 2021;7(3):265. https://doi.org/10.1016/j.trecan.2021.02.001 .
doi: 10.1016/j.trecan.2021.02.001
pubmed: 33596415
Tellez-Gabriel M, Heymann MF, Heymann D. Circulating tumor cells as a tool for assessing tumor heterogeneity. Theranostics. 2019;9(16):4580–94. https://doi.org/10.7150/thno.34337.PMID:31367241;PMCID:PMC6643448 .
doi: 10.7150/thno.34337.PMID:31367241;PMCID:PMC6643448
pubmed: 31367241
pmcid: 6643448
Miyamoto DT, Zheng Y, Wittner BS, Lee RJ, Zhu H, Broderick KT, et al. RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. Science. 2015;349(6254):1351–6. https://doi.org/10.1126/science.aab0917.PMID:26383955;PMCID:PMC4872391 .
doi: 10.1126/science.aab0917.PMID:26383955;PMCID:PMC4872391
pubmed: 26383955
pmcid: 4872391
Lang JE, Ring A, Porras T, Kaur P, Forte VA, Mineyev N, et al. RNA-Seq of circulating tumor cells in Stage II–III breast cancer. Ann Surg Oncol. 2018;25(8):2261–70. https://doi.org/10.1245/s10434-018-6540-4 (Epub 2018 Jun 4. PMID: 29868978; PMCID: PMC7065419).
doi: 10.1245/s10434-018-6540-4
pubmed: 29868978
pmcid: 7065419
Franses JW, Philipp J, Missios P, Bhan I, Liu A, Yashaswini C, et al. Pancreatic circulating tumor cell profiling identifies LIN28B as a metastasis driver and drug target. Nat Commun. 2020;11(1):3303. https://doi.org/10.1038/s41467-020-17150-3.PMID:32620742;PMCID:PMC7335061 .
doi: 10.1038/s41467-020-17150-3.PMID:32620742;PMCID:PMC7335061
pubmed: 32620742
pmcid: 7335061
Hofman P, Heeke S, Alix-Panabières C, Pantel K. Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients? Ann Oncol. 2019;30(9):1448–59. https://doi.org/10.1093/annonc/mdz196 (PMID: 31228184).
doi: 10.1093/annonc/mdz196
pubmed: 31228184
Yu W, Hurley J, Roberts D, Chakrabortty SK, Enderle D, Noerholm M, Breakefield XO, Skog JK. Exosome-based liquid biopsies in cancer: opportunities and challenges. Ann Oncol. 2021;32(4):466–77. https://doi.org/10.1016/j.annonc.2021.01.074 (Epub 2021 Feb 4 PMID: 33548389).
doi: 10.1016/j.annonc.2021.01.074
pubmed: 33548389
De Rubis G, Rajeev Krishnan S, Bebawy M. Liquid biopsies in cancer diagnosis, monitoring, and prognosis. Trends Pharmacol Sci. 2019;40(3):172–86. https://doi.org/10.1016/j.tips.2019.01.006 (Epub 2019 Feb 5 PMID: 30736982).
doi: 10.1016/j.tips.2019.01.006
pubmed: 30736982
Best MG, Sol N, Int Veld SGJG, Vancura A, Muller M, Niemeijer AN, et al. Swarm intelligence-enhanced detection of non-small-cell lung cancer using tumor-educated platelets. Cancer Cell. 2017;32(2):238–2529. https://doi.org/10.1016/j.ccell.2017.07.004.PMID:28810146;PMCID:PMC6381325 .
doi: 10.1016/j.ccell.2017.07.004.PMID:28810146;PMCID:PMC6381325
pubmed: 28810146
pmcid: 6381325
Kimura H, Suminoe M, Kasahara K, Sone T, Araya T, Tamori S, et al. Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). Br J Cancer. 2007;97(6):778–84. https://doi.org/10.1038/sj.bjc.6603949 .
doi: 10.1038/sj.bjc.6603949
pubmed: 17848912
pmcid: 2360394
Miyazawa H, Tanaka T, Nagai Y, Matsuoka M, Huqun SA, Udagawa K, et al. Peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based detection test for gefitinib-refractory T790M epidermal growth factor receptor mutation. Cancer Sci. 2008;99(3):595–600. https://doi.org/10.1111/j.1349-7006.2007.00706.x .
doi: 10.1111/j.1349-7006.2007.00706.x
pubmed: 18271876
Lang AH, Drexel H, Geller-Rhomberg S, Stark N, Winder T, Geiger K, et al. Optimized allele-specific real-time PCR assays for the detection of common mutations in KRAS and BRAF. J Mol Diagn. 2011;13(1):23–8.
doi: 10.1016/j.jmoldx.2010.11.007
Vogelstein B, Kinzler KW. PCR digital. Proc Natl Acad Sci USA. 1999;96:9236–41.
doi: 10.1073/pnas.96.16.9236
Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14(9):985–90.
doi: 10.1038/nm.1789
Hindson BJ, Ness KD, Masquelier DA, Belgrader P, Heredia NJ, Makarewicz AJ, et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal Chem. 2011;83:8604–10.
doi: 10.1021/ac202028g
Steensma DP, Ebert BL. Clonal hematopoiesis as a model for premalignant changes during aging. Exp Hematol. 2020;83:48–56. https://doi.org/10.1016/j.exphem.2019.12.001 .
doi: 10.1016/j.exphem.2019.12.001
pubmed: 31838005
Acuna-Hidalgo R, Sengul H, Steehouwer M, van de Vorst M, Vermeulen SH, Kiemeney LALM, Veltman JA, Gilissen C, Hoischen A. Ultra-sensitive sequencing identifies high prevalence of clonal hematopoiesis-associated mutations throughout adult life. Am J Hum Genet. 2017;101(1):50–64. https://doi.org/10.1016/j.ajhg.2017.05.013 .
doi: 10.1016/j.ajhg.2017.05.013
pubmed: 28669404
pmcid: 5501773
Hu Y, Ulrich BC, Supplee J, Kuang Y, Lizotte PH, Feeney NB, Guibert NM, Awad MM, Wong KK, Jänne PA, Paweletz CP, Oxnard GR. False-positive plasma genotyping due to clonal hematopoiesis. Clin Cancer Res. 2018;24(18):4437–43. https://doi.org/10.1158/1078-0432.CCR-18-0143 (Epub 2018 Mar 22. PMID: 29567812).
doi: 10.1158/1078-0432.CCR-18-0143
pubmed: 29567812
Swanton C, Venn O, Aravanis A, Hubbell E, Maddala T, Beausang JF, et al. Prevalence of clonal hematopoiesis of indeterminate potential (CHIP) measured by an ultra-sensitive sequencing assay: exploratory analysis of the Circulating Cancer Genome Atlas (CCGA) study. J Clin Oncol. 2018;36:12003.
doi: 10.1200/JCO.2018.36.15_suppl.12003
Young AL, Challen GA, Birmann BM, Druley TE. Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults. Nat Commun. 2016;22(7):12484.
doi: 10.1038/ncomms12484
Chan HT, Chin YM, Nakamura Y, Low S-K. Clonal hematopoiesis in liquid biopsy: from biological noise to valuable clinical implications. Cancers. 2020;12(8):2277. https://doi.org/10.3390/cancers12082277 .
doi: 10.3390/cancers12082277
pmcid: 7463455
Chan HT, Nagayama S, Chin YM, Otaki M, Hayashi R, Kiyotani K, et al. Clinical significance of clonal hematopoiesis in the interpretation of blood liquid biopsy. Mol Oncol. 2020;14(8):1719–30. https://doi.org/10.1002/1878-0261.12727 .
doi: 10.1002/1878-0261.12727
pubmed: 32449983
pmcid: 7400786
Mehrotra M, Singh RR, Chen W, Huang RSP, Almohammedsalim AA, Barkoh BA, et al. Study of preanalytic and analytic variables for clinical next-generation sequencing of circulating cell-free nucleic acid. J Mol Diagn. 2017;19(4):514–24.
doi: 10.1016/j.jmoldx.2017.03.003
Demuth C, Winther-Larsen A, Madsen AT, Meldgaard P, Sorensen BS. A method for treatment monitoring using circulating tumour DNA in cancer patients without targetable mutations. Oncotarget. 2018;9(57):31066–76.
doi: 10.18632/oncotarget.25779
Islam S, Zeisel A, Joost S, La Manno G, Zajac P, Kasper M, et al. Quantitative single-cell RNA-seq with unique molecular identifiers. Nat Methods. 2014;11:163–6.
doi: 10.1038/nmeth.2772
Best K, Oakes T, Heather JM, Shawe-Taylor J, Chain B. Computational analysis of stochastic heterogeneity in PCR amplification efficiency revealed by single molecule barcoding. Sci Rep. 2015;5:14629.
doi: 10.1038/srep14629
Kou R, Lam H, Duan H, Ye L, Jongkam N, Chen W, et al. Benefits and challenges with applying unique molecular identifiers in next generation sequencing to detect low frequency mutations. PLoS ONE. 2016;11(1):e0146638.
doi: 10.1371/journal.pone.0146638
Hashimshony T, Senderovich N, Avital G, Klochendler A, de Leeuw Y, Anavy L, et al. CEL-Seq2: sensitive highly-multiplexed single-cell RNA-Seq. Genome Biol. 2016;17:77. https://doi.org/10.1186/s13059-016-0938-8 .
doi: 10.1186/s13059-016-0938-8
pubmed: 27121950
pmcid: 4848782
Salk JJ, Schmitt MW, Loeb LA. Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations. Nat Rev Genet. 2018;19(5):269–85. https://doi.org/10.1038/nrg.2017.117 (Epub 2018 Mar 26. PMID: 29576615; PMCID: PMC6485430).
doi: 10.1038/nrg.2017.117
pubmed: 29576615
pmcid: 6485430
Laird CD, Pleasant ND, Clark AD, Sneeden JL, Hassan KM, Manley NC, et al. Hairpin-bisulfite PCR: assessing epigenetic methylation patterns on complementary strands of individual DNA molecules. Proc Natl Acad Sci USA. 2004;101(1):204–9.
doi: 10.1073/pnas.2536758100
Miner BE, Stöger RJ, Burden AF, Laird CD, Hansen RS. Molecular barcodes detect redundancy and contamination in hairpin-bisulfite PCR. Nucleic Acids Res. 2004;32(17):e135.
doi: 10.1093/nar/gnh132
McCloskey ML, Stöger R, Hansen RS, Laird CD. Encoding PCR products with batch-stamps and barcodes. Biochem Genet. 2007;45(11–12):761–7.
doi: 10.1007/s10528-007-9114-x
Hiatt JB, Patwardhan RP, Turner EH, Lee C, Shendure J. Parallel, tag-directed assembly of locally derived short sequence reads. Nat Methods. 2010;7(2):119–22. https://doi.org/10.1038/nmeth.1416 .
doi: 10.1038/nmeth.1416
pubmed: 20081835
pmcid: 2848820
Casbon JA, Osborne RJ, Brenner S, Lichtenstein CP. A method for counting PCR template molecules with application to next-generation sequencing. Nucleic Acids Res. 2011;39(12): e81. https://doi.org/10.1093/nar/gkr217 .
doi: 10.1093/nar/gkr217
pubmed: 21490082
pmcid: 3130290
Fu GK, Hu J, Wang PH, Fodor SP. Counting individual DNA molecules by the stochastic attachment of diverse labels. Proc Natl Acad Sci USA. 2011;108(22):9026–31. https://doi.org/10.1073/pnas.1017621108 .
doi: 10.1073/pnas.1017621108
pubmed: 21562209
pmcid: 3107322
Jabara CB, Jones CD, Roach J, Anderson JA, Swanstrom R. Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID. Proc Natl Acad Sci USA. 2011;108:20166–71. https://doi.org/10.1073/pnas.1110064108 .
doi: 10.1073/pnas.1110064108
pubmed: 22135472
pmcid: 3250168
Kinde I, Wu J, Papadopoulos N, Kinzler KW, Vogelstein B. Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci USA. 2011;108:9530–5.
doi: 10.1073/pnas.1105422108
Kivioja T, Vähärautio A, Karlsson K, Bonke M, Enge M, Linnarsson S, et al. Counting absolute numbers of molecules using unique molecular identifiers. Nat Methods. 2011;9(1):72–4. https://doi.org/10.1038/nmeth.1778 .
doi: 10.1038/nmeth.1778
pubmed: 22101854
Shiroguchi K, Jia TZ, Sims PA, Xie XS. Digital RNA sequencing minimizes sequence-dependent bias and amplification noise with optimized single-molecule barcodes. Proc Natl Acad Sci USA. 2012;109(4):1347–52. https://doi.org/10.1073/pnas.1118018109 .
doi: 10.1073/pnas.1118018109
pubmed: 22232676
pmcid: 3268301
Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra24. https://doi.org/10.1126/scitranslmed.3007094 .
doi: 10.1126/scitranslmed.3007094
pubmed: 24553385
pmcid: 4017867
Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545(7655):446–51.
doi: 10.1038/nature22364
Schmitt MW, Kennedy SR, Salk JJ, Fox EJ, Hiatt JB, Loeb LA. Detection of ultra-rare mutations by next-generation sequencing. Proc Natl Acad Sci USA. 2012;109(36):14508–13. https://doi.org/10.1073/pnas.1208715109 .
doi: 10.1073/pnas.1208715109
pubmed: 22853953
pmcid: 3437896
Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014;20(5):548–54. https://doi.org/10.1038/nm.3519 .
doi: 10.1038/nm.3519
pubmed: 24705333
pmcid: 4016134
Phallen J, Sausen M, Adleff V, Leal A, Hruban C, White J, et al. Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med. 2017;9(403):2415. https://doi.org/10.1126/scitranslmed.aan2415 .
doi: 10.1126/scitranslmed.aan2415
Chaudhuri AA, Chabon JJ, Lovejoy AF, Newman AM, Stehr H, Azad TD, et al. Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer Discov. 2017;7(12):1394–403. https://doi.org/10.1158/2159-8290.CD-17-0716 (Epub 2017 Sep 24. PMID: 28899864; PMCID: PMC5895851).
doi: 10.1158/2159-8290.CD-17-0716
pubmed: 28899864
pmcid: 5895851
Chabon JJ, Hamilton EG, Kurtz DM, Esfahani MS, Moding EJ, Stehr H, et al. Integrating genomic features for non-invasive early lung cancer detection. Nature. 2020;580(7802):245–51. https://doi.org/10.1038/s41586-020-2140-0 (Epub 2020 Mar 25 PMID: 32269342).
doi: 10.1038/s41586-020-2140-0
pubmed: 32269342
pmcid: 8230734
MacConaill LE, Burns RT, Nag A, Coleman HA, Slevin MK, Giorda K, et al. Unique, dual-indexed sequencing adapters with UMIs effectively eliminate index cross-talk and significantly improve sensitivity of massively parallel sequencing. BMC Genomics. 2018;19:30. https://doi.org/10.1186/s12864-017-4428-5 .
doi: 10.1186/s12864-017-4428-5
pubmed: 29310587
pmcid: 5759201
Dunwell TL, Dailey SC, Yu J, Becker PW, Scaife S, Richman SD, et al. Adaptor template oligo-mediated sequencing (ATOM-Seq): a versatile and ultra-sensitive UMI-based NGS library preparation technology, for use with cfDNA and cfRNA. bioRxiv. 2020. https://doi.org/10.1101/2020.07.10.152405 .
doi: 10.1101/2020.07.10.152405
Zheng Z, Liebers M, Zhelyazkova B, Cao Y, Panditi D, Lynch KD, et al. Anchored multiplex PCR for targeted next-generation sequencing. Nat Med. 2014;20(12):1479–84. https://doi.org/10.1038/nm.3729 .
doi: 10.1038/nm.3729
pubmed: 25384085
Xu C, Nezami Ranjbar M, Wu Z, Di Carlo J, Wany Y. Detecting very low allele fraction variants using targeted DNA sequencing and a novel molecular barcode-aware variant caller. BMC Genomics. 2017;18:5. https://doi.org/10.1186/s12864-016-3425-4 .
doi: 10.1186/s12864-016-3425-4
pubmed: 28049435
pmcid: 5209917
US Food and Drug Administration. FoundationOne® Liquid CDx (F1 Liquid CDx). FDA (2020). https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200016A.pdf .
US Food and Drug Administration. Guardant360® CDx. FDA (2020). https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200010A.pdf .
Woodhouse R, Li M, Hughes J, Delfosse D, Skoletsky J, Ma P, et al. Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin. PLoS ONE. 2020;15(9):e0237802. https://doi.org/10.1371/journal.pone.0237802.PMID:32976510;PMCID:PMC7518588 .
doi: 10.1371/journal.pone.0237802.PMID:32976510;PMCID:PMC7518588
pubmed: 32976510
pmcid: 7518588
Lanman RB, Mortimer SA, Zill OA, Sebisanovic D, Lopez R, Blau S, et al. Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA. PLoS ONE. 2015;10(10):e0140712. https://doi.org/10.1371/journal.pone.0140712.PMID:26474073;PMCID:PMC4608804 .
doi: 10.1371/journal.pone.0140712.PMID:26474073;PMCID:PMC4608804
pubmed: 26474073
pmcid: 4608804
Odegaard JI, Vincent JJ, Mortimer S, Vowles JV, Ulrich BC, Banks KC, et al. Validation of a plasma-based comprehensive cancer genotyping assay utilizing orthogonal tissue- and plasma-based methodologies. Clin Cancer Res. 2018;24(15):3539–49. https://doi.org/10.1158/1078-0432.CCR-17-3831 (Epub 2018 Apr 24 PMID: 29691297).
doi: 10.1158/1078-0432.CCR-17-3831
pubmed: 29691297
Zill OA, Banks KC, Fairclough SR, Mortimer SA, Vowles JV, Mokhtari R, et al. The landscape of actionable genomic alterations in cell-free circulating tumor DNA from 21,807 advanced cancer patients. Clin Cancer Res. 2018;24(15):3528–38. https://doi.org/10.1158/1078-0432.CCR-17-3837 (Epub 2018 May 18 PMID: 29776953).
doi: 10.1158/1078-0432.CCR-17-3837
pubmed: 29776953
Leighl NB, Page RD, Raymond VM, Daniel DB, Divers SG, Reckamp KL, et al. Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer. Clin Cancer Res. 2019;25(15):4691–700. https://doi.org/10.1158/1078-0432.CCR-19-0624 (Epub 2019 Apr 15 PMID: 30988079).
doi: 10.1158/1078-0432.CCR-19-0624
pubmed: 30988079
Illumina 2018. Detection of low-frequency variants in cfDNA using TruSight Tumor 170 with the TruSight UMI Toolkit. https://www.illumina.com/content/dam/illumina-marketing/documents/products/technotes/trusight-umi-trusight-tumor-170-app-note-1000000050427.pdf .
De Luca G, Lastraioli S, Conte R, Mora M, Genova C, Rossi G, et al. Performance of the oncomine
doi: 10.3390/app10082895
Dono M, De Luca G, Lastraioli S, Anselmi G, Dal Bello MG, Coco S, et al. Tag-based next generation sequencing: a feasible and reliable assay for EGFR T790M mutation detection in circulating tumor DNA of non small cell lung cancer patients. Mol Med. 2019;25(1):15. https://doi.org/10.1186/s10020-019-0082-5 .
doi: 10.1186/s10020-019-0082-5
pubmed: 31029076
pmcid: 6487061
Papadopoulou E, Tsoulos N, Tsantikidi K, Metaxa-Mariatou V, Stamou PE, Kladi-Skandali A, et al. Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients. PLoS ONE. 2019;14(12):e0226853. https://doi.org/10.1371/journal.pone.0226853.PMID:31860648;PMCID:PMC6924668 .
doi: 10.1371/journal.pone.0226853.PMID:31860648;PMCID:PMC6924668
pubmed: 31860648
pmcid: 6924668
Vollbrecht C, Lehmann A, Lenze D, Hummel M. Validation and comparison of two NGS assays for the detection of EGFR T790M resistance mutation in liquid biopsies of NSCLC patients. Oncotarget. 2018;9:18529–39.
doi: 10.18632/oncotarget.24908
Weber S, Spiegl B, Perakis SO, Ulz CM, Abuja PM, Kashofer K, et al. Technical evaluation of commercial mutation analysis platforms and reference materials for liquid biopsy profiling. Cancers (Basel). 2020;12(6):1588. https://doi.org/10.3390/cancers12061588.PMID:32560092;PMCID:PMC7352370 .
doi: 10.3390/cancers12061588.PMID:32560092;PMCID:PMC7352370
Vessies DC, Linders TC, Ramkisoensing KL, Nederlof PM, Meijer GA, Monkhorst K, et al. Technical validation of Roche AVENIO sequencing platform for liquid biopsies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29–Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1381.
Alix-Panabieres C, Pantel K. Circulating tumor cells: liquid biopsy of cancer. Clin Chem. 2013;59:110–8.
doi: 10.1373/clinchem.2012.194258
Huang X, Gao P, Song Y, Sun J, Chen X, Zhao J, et al. Meta-analysis of the prognostic value of circulating tumor cells detected with the cell search system in colorectal cancer. BMC Cancer. 2015;15:202. https://doi.org/10.1186/s12885-015-1218-9.PMID:25880692;PMCID:PMC4389311 .
doi: 10.1186/s12885-015-1218-9.PMID:25880692;PMCID:PMC4389311
pubmed: 25880692
pmcid: 4389311
Tol J, Koopman M, Miller MC, Tibbe A, Cats A, Creemers GJ, et al. Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. Ann Oncol. 2010;21(5):1006–12. https://doi.org/10.1093/annonc/mdp463 (Epub 2009 Oct 27 PMID: 19861577).
doi: 10.1093/annonc/mdp463
pubmed: 19861577
Krebs MG, Sloane R, Priest L, Lancashire L, Hou JM, Greystoke A, et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol. 2011;29(12):1556–63. https://doi.org/10.1200/JCO.2010.28.7045 (Epub 2011 Mar 21 PMID: 21422424).
doi: 10.1200/JCO.2010.28.7045
pubmed: 21422424
Sparano J, O’Neill A, Alpaugh K, Wolff AC, Northfelt DW, Dang CT, et al. Association of circulating tumor cells with late recurrence of estrogen receptor-positive breast cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2018;4(12):1700–6. https://doi.org/10.1001/jamaoncol.2018.2574.PMID:30054636;PMCID:PMC6385891 .
doi: 10.1001/jamaoncol.2018.2574.PMID:30054636;PMCID:PMC6385891
pubmed: 30054636
pmcid: 6385891
Alix-Panabières C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov. 2016;6:479–91.
doi: 10.1158/2159-8290.CD-15-1483
Lianidou E, Pantel K. Liquid Biopsies. Genes Chromosomes Cancer. 2019;58:219–32.
doi: 10.1002/gcc.22695
Ma N, Jeffrey SS. Deciphering cancer clues from blood. Science. 2020;367(6485):1424–5. https://doi.org/10.1126/science.abb0736 (PMID: 32217712).
doi: 10.1126/science.abb0736
pubmed: 32217712
Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351:781–91.
doi: 10.1056/NEJMoa040766
Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res. 2006;12:4218–24.
doi: 10.1158/1078-0432.CCR-05-2821
Kanwar N, Hu P, Bedard P, Clemons M, McCready D, Done SJ. Identification of genomic signatures in circulating tumor cells from breast cancer. Int J Cancer. 2015;137:332–44.
doi: 10.1002/ijc.29399
Lasken RS, Egholm M. Whole genome amplification: abundant supplies of DNA from precious samples or clinical specimens. Trends Biotechnol. 2003;21:531–5.
doi: 10.1016/j.tibtech.2003.09.010
Hughes S, Arneson N, Done S, Squire J. The use of whole genome amplification in the study of human disease. Prog Biophys Mol Biol. 2005;88:173–89.
doi: 10.1016/j.pbiomolbio.2004.01.007
Pinard R, deWinter A, Sarkis G, Gerstein MB, Tartaro KR, Plant RN, et al. Assessment of whole genome amplification-induced bias through high-throughput, massively parallel whole genome sequencing. BMC Genom. 2006;7:216.
doi: 10.1186/1471-2164-7-216
Huang L, Ma F, Chapman A, Lu S, Xie XS. Single-cell whole-genome amplification and sequencing: Methodology and applications. Annu Rev Genom Hum Genet. 2015;16:79–102.
doi: 10.1146/annurev-genom-090413-025352
Zhu Z, Qiu S, Shao K, Hou Y. Progress and challenges of sequencing and analyzing circulating tumor cells. Cell Biol Toxicol. 2018;34:405–15.
doi: 10.1007/s10565-017-9418-5
De Luca G, Cardinali B, Del Mastro L, Lastraioli S, Carli F, Ferrarini M, et al. Optimization of a WGA-free molecular tagging-based NGS protocol for CTCs mutational profiling. Int J Mol Sci. 2020;21:4364.
doi: 10.3390/ijms21124364
Vander Heiden JA, Yaari G, Uduman M, Stern JN, O’Connor KC, Hafler DA, et al. pRESTO: a toolkit for processing high-throughput sequencing raw reads of lymphocyte receptor repertoires. Bioinformatics. 2014;30(13):1930–2. https://doi.org/10.1093/bioinformatics/btu138 (Epub 2014 Mar 10. PMID: 24618469; PMCID: PMC4071206).
doi: 10.1093/bioinformatics/btu138
pubmed: 24618469
pmcid: 4071206
Shugay M, Zaretsky AR, Shagin DA, Shagina IA, Volchenkov IA, Shelenkov AA, et al. MAGERI: Computational pipeline for molecular-barcoded targeted resequencing. PLoS Comput Biol. 2017;13(5): e1005480. https://doi.org/10.1371/journal.pcbi.1005480.PMID:28475621;PMCID:PMC5419444 .
doi: 10.1371/journal.pcbi.1005480.PMID:28475621;PMCID:PMC5419444
pubmed: 28475621
pmcid: 5419444
Clement K, Farouni R, Bauer DE, Pinello L. AmpUMI: design and analysis of unique molecular identifiers for deep amplicon sequencing. Bioinformatics. 2018;34(13):i202–10. https://doi.org/10.1093/bioinformatics/bty264.PMID:29949956;PMCID:PMC6022702 .
doi: 10.1093/bioinformatics/bty264.PMID:29949956;PMCID:PMC6022702
pubmed: 29949956
pmcid: 6022702